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A B S T R A C T
Purpose
In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy
after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST).
Patients and Methods
Patients were randomly assigned to 2 years of imatinib 400 mg daily or no further therapy after
surgery. The primary end point was overall survival; relapse-free survival (RFS), relapse-free
interval, and toxicity were secondary end points. In 2009, given the concurrent improvement in
prognosis of patients with advanced GIST, we changed the primary end point to imatinib
failure–free survival (IFFS), with agreement of the independent data monitoring committee. We
report on a planned interim analysis.
Results
A total of 908 patients were randomly assigned between December 2004 and October 2008: 454
to imatinib and 454 to observation. Of these, 835 patients were eligible. With a median follow-up
of 4.7 years, 5-year IFFS was 87% in the imatinib arm versus 84% in the control arm (hazard ratio,
0.79; 98.5% CI, 0.50 to 1.25; P .21); RFS was 84% versus 66% at 3 years and 69% versus 63%
at 5 years (log-rank P  .001); and 5-year overall survival was 100% versus 99%, respectively.
Among 528 patients with high-risk GIST by local pathologist, 5-year IFFS was 79% versus 73%;
among 336 centrally reviewed high-risk patients, it was 77% versus 73%, respectively.
Conclusion
This study confirms that adjuvant imatinib has an overt impact on RFS. No significant
difference in IFFS was observed, although in the high-risk subgroup there was a trend in favor
of the adjuvant arm. IFFS was conceived as a potential end point in the adjuvant setting
because it is sensitive to secondary resistance, which is the main adverse prognostic factor in
patients with advanced GIST.
J Clin Oncol 33:4276-4283. © 2015 by American Society of Clinical Oncology
INTRODUCTION
GI stromal tumors (GISTs) are rare cancers, the
treatment of which in the advanced stages of disease
has been revolutionized by the introduction of ty-
rosine kinase inhibitors targeting KIT and/or
platelet-derived growth factor receptor alpha.1,2
From the earliest use of imatinib in advanced GIST,
it was clear that the drug was highly effective, and
this was confirmed with longer follow-up.3-6 The
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main limiting factor is secondary resistance, which is often deter-
mined by the occurrence in cellular subclones of secondary muta-
tions in the same oncogene initially affected by the primary
mutation. The median time to this secondary resistance is 1 to 3
years in the advanced setting.5,6
Thus, from the early years of imatinib use in advancedGIST, the
sarcoma community conceived trials to test this therapy in the adju-
vant setting.7,8 In 2004, the European Organisation for Research and
Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma
Group launched a randomized clinical trial of adjuvant imatinib in
collaboration with the Australasian Gastro-Intestinal Trials Group,
UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and
SpanishGroup forResearchonSarcomas.Weaimed to select patients
with GIST with an intermediate or high risk of relapse, following the
consensus classification used at the time, aiming to exclude only pa-
tients with a low risk of relapse.We assumed that a benefit in relapse-
free survival (RFS) could be expected, given the high effectiveness of
imatinib in patients with advanced GIST. However, this expected
benefit would be meaningful only if it resulted in an increase in the
cure rate or a substantial delay in relapse without any decrease in the
time to progression, when relapsing patients are rechallenged with
imatinib. Therefore,we chose overall survival (OS) as theprimary end
point of our trial. However, at a planned interim analysis in March
2009, it became evident to the study independent data monitoring
committee (IDMC) that the likely overall duration of the trial would
make it prohibitive to keepOS as the primary end point, so there was
a strong recommendation that the trial have an amended primary
end point. Because RFS alsomay not have served as a satisfactory trial
end point, we identified an alternative end point—imatinib mono-
therapy failure–free survival (IFFS; ie, time to resistance to ima-
tinib)—determined by the date of switching to an alternate tyrosine
kinase inhibitor. In agreementwith the IDMC,weadopted IFFS as the
new primary end point of the trial. In June 2012, the IDMC recom-
mended the release of the interimanalysis resultswith continuationof
the study to the planned final analysis. This article reports the interim
analysis, as per the amended study protocol, focusing on the new
primary study end point.
PATIENTS AND METHODS
Study Design and Participants
Thiswasa randomized,open-label,multicenterphase III trial performed
at 112 hospitals in 12 countries (Australia, Belgium, Denmark, France, Ger-
many, Italy, New Zealand, Poland, Singapore, Spain, the Netherlands, and
UnitedKingdom). Patients could be randomly assigned if they had a histolog-
ically proven diagnosis of primary resectedGIST, with positive immunostain-
ing for KIT (CD117), with risk of relapse documented on the surgical
specimen according to the 2002 National Institutes of Health (NIH) Consen-
susDiagnosis of GIST9 as high risk (tumor size 10 cm,mitotic rate 10/50
HPF, or tumor size 5 cm andmitotic rate 5/50HPF) or intermediate risk
(tumor size5 cmandmitotic rate 6/50 to 10/50HPFor tumor size5 to 10
cm andmitotic rate 5/50HPF). Surgery had to be performed from 2weeks
to 3months before randomassignment, and surgicalmargins had to be either
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Fig 1. CONSORT diagram. PD, progressive disease.
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R0 or R1. Intraoperative tumor rupture was coded as R1 and properly re-
corded by a panel of expert surgeons who had access to the original surgical
reports. No prior radiation therapy or systemic treatment for GIST was al-
lowed.Distantmetastaseswerenotpermitted, includinganyperitoneal lesions
not contiguous to the primary tumor; regional positive lymph nodes were
permitted, if completely excised. Participants had to be age  18 years and
have WHO performance status 0 to 2. Cardiac ejection function had to be
assessed at baseline andduring treatment. Severe and/oruncontrolled concur-
rent medical disease was not allowed, nor was any prior or ongoing other
malignancy, except adequately treated basal cell or squamous cell skin cancer,
in situ cervical cancer, or cancer adequately treated with eradicative intent
from which the patient had been continuously free for  5 years. Eligible
patients were randomly assigned (using minimization) after surgery either to
receive imatinib 400mg per day for 2 years or to be observed without further
antitumoral therapy. Randomization was stratified by center, risk category
(high v intermediate), tumor site (gastric v other), and resection level (R0 v
R1). Neither patients nor investigators were masked to treatment allocation.
The study was approved by the institutional review board and/or ethics com-
mittee of each participating institution.
Methods
In the adjuvant arm, imatinib was administered for 2 years, and treat-
ment was discontinued in case of relapse of disease, unacceptable toxicity, or
withdrawal from study.Dosemodifications for hematologic and nonhemato-
logic adverse events were foreseen in the protocol. The study protocol did not
specify the treatment to be administered after relapse. However, guidelines
were circulated after amending the protocol, recommending restarting ima-
tinib at a dose of 400 mg daily or possibly 800 mg for patients with an exon 9
KIT-mutated GIST, with the only logical exception being those patients who
experienced relapse during imatinib therapy.
While receiving treatment, patients underwent follow-up everyweek for
the first month, then every 2 weeks for the secondmonth, thenmonthly until
the end of the sixthmonth of therapy, and subsequently every 3months until
treatment discontinuation. Chest x-ray and abdominal computed tomogra-
phy scanormagnetic resonance imagingwere requiredwithin 1monthbefore
randomassignment and every 3months thereafter. After the end of treatment
(treated arm) and after random assignment (control arm), follow-up was
performed every 3months until 2 years after randomassignment, then every 4
months until 5 years had elapsed, and thereafter at least annually, at the
discretion of the responsible physician.
Outcomes
The study was originally designed with OS as the primary end point.
Secondary end points were RFS, relapse-free interval, incidence of adverse
events, and, as of December 2007, time to imatinib failure. The initial esti-
mated sample size of 400 patients to be recruited over 5 years was increased to
900 patients in December 2007 to adjust for the larger-than-expected sub-
group of patients recruited with low- and intermediate-risk tumors and the
higher-than-expected survival rate in the control group. In March 2009, it
became clear that the planned interim analysis of OS would not be feasible
within a reasonable timeline; therefore, the IDMC recommended changing
the primary end point. IFFS was chosen, and the study design was updated
accordinglyby an independent statistician. IFFSwasdetermined fromthedate
of random assignment to the date of the start of a new systemic treatment, the
start of a combination of imatinib with a new systemic treatment, or death
resulting fromany cause,whichever occurredfirst.OSwasmeasured from the
date of random assignment to the date of death, whatever the cause. RFS was
measured from the date of random assignment to the date of relapse (local
and/or distant) or death, whichever occurred first. In the absence of such
events, patientswere censored at thedate of last follow-upor the clinical cutoff
date, whichever occurred first. Relapse-free interval was measured from the
date of random assignment to the date of relapse. Death without relapse was
considered a competing risk. Adverse events were graded according to the
Common Terminology Criteria for Adverse Events (version 3.0).
Statistical Analysis
Improvement of IFFS was considered clinically significant if the risk of
imatinib failurewasdecreasedby34.5%in the adjuvant treatment armrelative
to the reference group, corresponding to a hazard ratio (HR)  0.655. To
detect such a difference using a two-sided log-rank test and allowing for one
interim analysis, a total of 196 events needed to be observed (  0.2). An
interim analysis was planned and carried out after observation of 98 events,
testing both for H0 and H1. A power family error spending function with a
boundaryparameter of 0.2wasused.Anoverall level of 0.05 (two-sided test)
was used, with a significance level of .015 dedicated to the interim analysis.
All efficacy analyses were carried out according to the intent-to-treat
policy.These time-to-event endpointswereestimatedusing theKaplan-Meier
method and compared between treatment arms using two-sided log-rank
tests. Safety analysis included patients who had started adjuvant therapy.
East software (version 5; Cytel, Cambridge, MA) was used to calculate
sample size and stopping boundaries; we performed all other statistical analy-
ses with SAS software (version 9.3; SAS Institute, Cary, NC). This report is
based on all data available on January 1, 2012.
RESULTS
In total, 908 patients were randomly assigned between December 8,
2004, andOctober 20, 2008: 454 to the adjuvant imatinib armand454
to the observation arm (Fig 1). All patient files were reviewed by the
study coordinator and the clinical researchphysician at EORTChead-
quarters. Seventy-two patients (7.9%) did not meet the eligibility
criteria: 67hadan inappropriatediagnosis, twowere ineligiblebecause
of prior treatment, one had concurrent malignant disease, one had a
prior cancer 5 years ago, and one had a presentation highly sugges-
tiveof retroperitoneal sarcoma.Medianagewas59years (interquartile
range [IQR],49 to68); 51%weremen,86%hadperformance statusof
0, and 55% had a gastric GIST (Table 1). Table 2 summarizes the
baseline risk level of enrolled patients: 380 patients (42%) were iden-
tified as low or intermediate risk and 528 (58%) as high risk. Central
pathology reviewwas available for 696 patients.Median time between
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
No. (%)
Observation Arm
(n  454)
Imatinib Adjuvant Arm
(n  454) Total (N  908)
PS
0 380 (83.7) 399 (87.9) 779 (85.8)
1 74 (16.3) 54 (11.9) 128 (14.1)
2 0 (0.0) 1 (0.2) 1 (0.1)
Sex
Male 234 (51.5) 232 (51.1) 466 (51.3)
Female 220 (48.5) 222 (48.9) 442 (48.7)
Age, years
 20 1 (0.2) 3 (0.7) 4 (0.4)
20-40 29 (6.4) 52 (11.5) 81 (8.9)
40-60 223 (49.1) 189 (41.6) 412 (45.4)
 60 201 (44.3) 210 (46.3) 411 (45.3)
Median 58 59 59
Range 20-89 18-86 18-89
Q1-Q3 49-68 48-67 49-68
Tumor site
Gastric 253 (55.7) 250 (55.1) 503 (55.4)
Other 201 (44.3) 204 (44.9) 405 (44.6)
Abbreviations: PS, performance status; Q, quartile.
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last surgery and random assignment was 67 days (range, 13 to 112).
Eighty-four percent of patients had an R0 resection.
Six patients did not start their allocated treatment: one patient in
theobservationarmreceived imatinibat another center, threepatients
refused adjuvant imatinib, one did not return to the clinic after being
randomly assigned, and one had a postoperative fistula (Fig 1). Of the
remaining 449 patients in the adjuvant imatinib arm, 336 (75%)
completed 2 years of treatment (two patients continued with therapy
for an extra half year); 22 (4.9%) stopped because of progression, 56
(12.5%) stopped because of toxicity (more information provided in
Appendix Table A1, online only), 20 (4.5%) refused to follow the
protocol, six discontinued because they were ineligible (five did not
have GIST, and one had concurrent malignant disease), four devel-
oped a second cancer, and four stopped for other reasons. Among the
113 patients who discontinued treatment, 52 (46%) did so within 6
months. Themost common grade 3 to 4 toxicities are summarized in
Appendix Table A2 (online only).
Median follow-up was 4.7 years (IQR, 4.0 to 5.3) in the imatinib
armand4.6 years (IQR, 3.8 to5.2) in theobservational arm.Figure 2A
shows the IFFS curves by treatment arm; there was no significant
difference (HR, 0.79; 98.5% CI, 0.50 to 1.25; P .21). A total of 793
patients remained imatinib failure free (imatinib arm, n  402 v
observational arm, n 391); 92 patients (n 40 v 52) were switched
to a systemic treatmentother than imatinib (including62 to sunitinib,
10 to nilotinib, and six to masitinib); 23 patients (n 12 v 11) died
without starting new systemic treatment.
Relapse occurred in 282patients (imatinib arm, n 121 vobser-
vational arm, n 161), with RFS significantly better in the adjuvant
imatinib arm (84% v 66% at 3 years; 69% v 63% at 5 years; log-rank
P  .001; Fig 2B). OS is summarized in Figure 2C: 62 patients died
(n  33 v 29), mostly because of progressive disease (22 v 23), but
survivaldidnotdifferbetweenthe twotreatmentarms(5-year survival
rate: imatinib arm, 91.8% v observational arm, 92.7%). Sensitivity
analyseswith stratifiedCoxproportionalhazardsmodels showedsim-
ilar results (data not shown).
Onrelapse,105patients receivedsalvage imatinib.Figure3shows
IFFS broken down between the intermediate- and the high-risk sub-
groups, asdefinedaccording to theNIH2002consensus classification.
An additional nonpreplanned analysis was performed following the
criteria of the more recent Armed Forces Institute of Pathology risk
classification8 of ruptured, high-risk (gastric:  5 cm and  five
mitoses; nongastric:  10 cm or  five mitoses), and low- or
intermediate-risk tumors (everything else). Figure 4 shows IFFS, RFS,
and OS according to this classification, with a statistically significant
difference in RFS, a nonstatistically significant trend in IFFS, and no
difference in OS.
No significant differences in IFFS were found in the sub-
group of patients with a tumor rupture. Figure 5 shows that
their RFS continues to show differences according to baseline
risk, despite the tumor rupture.
DISCUSSION
This randomized trial of adjuvant imatinib for 2 years versus observa-
tion in patients with resected localized GIST showed no significant
Table 2. Baseline Risk
Characteristic
No. (%)
Histopathology by Local Pathologist Histopathology by Central Review
Observation Arm
(n  454)
Imatinib Adjuvant
Arm (n  454) Total (N  908)
Observation Arm
(n  454)
Imatinib Adjuvant
Arm (n  454) Total (N  908)
Tumor
Non-GIST 5 (1.1) 6 (1.3) 11 (1.2)
GIST 454 (100.0) 454 (100.0) 908 (100.0) 333 (73.3) 351 (77.3) 684 (75.3)
Unknown 0 (0.0) 1 (0.2) 1 (0.1)
Not reviewed 116 (25.6) 96 (21.1) 212 (23.3)
Mitotic rate, HPF
 5/50 220 (48.5) 201 (44.3) 421 (46.4) 172 (37.9) 180 (39.6) 352 (38.8)
5-10/50 102 (22.5) 110 (24.2) 212 (23.3) 61 (13.4) 81 (17.8) 142 (15.6)
 10/50 132 (29.1) 143 (31.5) 275 (30.3) 99 (21.8) 92 (20.3) 191 (21.0)
Not reviewed 122 (26.9) 101 (22.2) 223 (24.6)
Tumor size, cm
 2 2 (0.4) 1 (0.2) 3 (0.3) 5 (1.1) 0 (0.0) 5 (0.6)
2-5 43 (9.5) 53 (11.7) 96 (10.6) 23 (5.1) 46 (10.1) 69 (7.6)
5-10 290 (63.9) 283 (62.3) 573 (63.1) 222 (48.9) 212 (46.7) 434 (47.8)
 10 119 (26.2) 117 (25.8) 236 (26.0) 83 (18.3) 91 (20.0) 174 (19.2)
Not reviewed 121 (26.7) 105 (23.1) 226 (24.9)
Risk category
Very low 2 (0.4) 0 (0.0) 2 (0.2)
Low 7 (1.5) 2 (0.4) 9 (1.0) 13 (2.9) 19 (4.2) 32 (3.5)
Intermediate 185 (40.7) 186 (41.0) 371 (40.9) 150 (33.0) 162 (35.7) 312 (34.4)
High 262 (57.7) 266 (58.6) 528 (58.1) 168 (37.0) 168 (37.0) 336 (37.0)
Not reviewed 121 (26.7) 105 (23.1) 226 (24.9)
Abbreviation: GIST, GI stromal tumor.
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difference in terms of IFFS, although in a nonpreplanned subgroup
analysis a trend was observed in patients with high-risk tumors in
favor of adjuvant therapy after complete surgery. This trial confirms
the results of the two other published trials of adjuvant imatinib in
patients with localized GIST (ie, RFS is substantially improved by
adjuvant imatinib).9,10 However,most of the benefit is lost after 1 to 3
years from the end of the adjuvant treatment period. Then, delaying
relapsewithout amajor decrease in the relapse ratemayhave a limited
impactonOSofhigh-riskpatients, as shown inanother trial, although
inour trialonlya longer follow-upwill allowus to fully exploreOSand
the surrogate meaning of IFFS. However, the trend of IFFS in the
adjuvant arm at least suggests that exposure to imatinib in the adju-
vant setting does not induce a selection pressure toward secondary
resistance, at least within the time interval that adjuvant imatinib was
administered in this study.
Aweakness of this trial is that almost half of the enrolled patients
had an intermediate risk of relapse according to current risk classifi-
cations. When conceiving the trial, we decided to include a range of
risks to assess the extent of the benefit across the risk categories.
Subsequently, the intermediate-risk category of the 2002NIH con-
sensus classification turned out to include a proportion of patients
who had a low risk of relapse.9,10,11 This is one of the main reasons
why this trial was repeatedly amended to preserve its statistical
power regarding substantial-risk patients. The analysis was there-
fore also broken down according to risk category as defined by the
new Armed Forces Institute of Pathology classification, which
more accurately reflects what is currently known about the risk of
relapse across patients with localized GIST.8
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We included patients with both R0 and R1 resections, given the
lack of definitive proof that R1 patients have a worse prognosis, using
marginal status as a stratification criterion.12 We also included pa-
tientswhohad tumor rupturewithin theR1 stratum.Today,weknow
that tumor rupture substantially worsens prognosis of patients with
GIST.13 The proportion of these patients in this trial was 11%. Inter-
estingly, we detected that the risk of relapse estimated with the three
mainprognostic factorsmaybreakdown tumor rupture intodifferent
risk categories. Numbers are low, but it is possible that the inherent
risk of relapse is not negligible in determining the final risk of patients
with tumor rupture and also that different kinds of tumor rupture
may actually exist. In this trial, a panel of surgeons reviewed surgical
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reports in the original languages. Their findingswill be the subject of a
separate report.
In our trial, we centralized tumor samples to carry out muta-
tional analysis. The final results of this analysis are still not available
and will be the subject of a separate report. This will allow an assess-
mentof thebenefitof imatinib innon–exon11KIT-mutatedGIST, as
recently published with regard to the American College of Surgeons
OncologyGroup trial.14 Thus,wewill be able to estimate the effective-
ness of adjuvant imatinib in imatinib-insensitive mutations and in
wild-type GIST. Unfortunately, with the lack of any planned increase
in dose for exon 9 KIT-mutated GIST, we will not be in a position to
determine whether a lack of benefit, if any, in this category could be
correctedby treatingpatientswith800mg, as currently recommended
by some institutions.15
Clearly, a crucial finding of adjuvant trials in GIST, including
ours, has been that stopping adjuvant therapy is followedby relapse in
at least most patients expected to experience relapse in the absence of
any adjuvant therapy. It follows that adjuvant imatinib therapy does
not seem to cure minimum residual disease in patients with resected
GIST. Of course, the most logical consequence for clinical research is
the attempt to prolong treatment duration, using the example of
adjuvant hormonal therapies in hormone-sensitive cancers. We be-
lieve that this should be confined to the clinical research setting, not
extended to clinical practice, for the same reasons why we originally
chose to carry out a randomized clinical trial with a no-treatment arm
having OS as its primary end point. In fact, trials should rule out a
detrimental effect of prolonging the adjuvant treatment in terms of an
earlier occurrence of secondary resistance. So far, using imatinib for 1,
2, or 3 years in the adjuvant setting has not resulted in any detrimental
effect when the same therapy has been used on relapse.
Inthissense,ourprimaryendpoint(ie, survival interval toswitching
to alternate tyrosine kinase inhibitor from first used in the individual
patient)will be validated—ornot—byOSdataon longer follow-up. If it
is, itcouldbeusedasanintermediateendpointtoanswerfuturequestions
on adjuvant molecularly targeted therapies in GIST and possibly other
solid cancers. Of course, one should be aware of its inherent weaknesses.
Themain one is that it assumes that secondary resistance is an essentially
irrecoverable outcome. So far, this is the case, by and large, in GIST, but
clearlywe all hope that additional-line agents, among those already avail-
ableandthoseunder intense research,will substantially alter thecourseof
advanced disease after secondary resistance.16,17 The second limitation is
thatprotocolsdesignedfortheadjuvantuseofadrugshouldalsotakeinto
account treatment guidelines for relapse. In our trial, this was not done,
althoughwelaterdisseminatedguidelines toallparticipatingcenters, thus
limiting the proportion of patients who did not receive imatinib as their
firsttreatmentonrelapse.However,wecarriedoutsensitivityanalysesand
ruled out that the outcome of these patients under an intent-to-treat
approachwould have altered the general conclusions of this trial.
In the end, this trial adds to available evidence on the efficacy of
adjuvant imatinib in GIST. We can confirm that RFS is significantly
improved by adjuvant targeted therapy. It follows that a survival
benefit would be consistent with the trend seen in our potential sur-
rogate end point in the high-risk subgroup, although this will need to
be assessed with longer follow-up. The issue of optimum adjuvant
treatment duration remains a question for clinical research. Another
question is whether new strategies of administering targeted therapies
may be more effective (eg, by rotating regimens or combinations of
more than one targeted agent), possibly guided by molecular bio-
markers during treatment, such as liquid biopsy and others.18
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Table A1. Toxicities Resulting in Early Stopping of Treatment Reported by Treating Physician for Each Patient
Duration of Treatment (days) Toxicity
3 Nausea and anorexia
19 Myocardial ischemia
24 Nausea and vomiting
27 Edema, hematomas, cramps
32 Rash, alopecia, neutropenia
34 Emesis
39 Diarrhea (treatment related)
40 Severe nausea and asthenia
42 Dyspnea, facial and periorbital edema
43 Dyspnea, fever, vomiting, diarrhea
52 Rash, edema, eosinophilia
56 Hepatic cytolysis
59 Hepatitis
63 Suspected pulmonary toxicity
71 Increase of transaminase
75 Cutaneous toxicity
83 Edema of superior and inferior limbs with cutaneous desquamation palpebral edema
86 Syncope, fatigue, anorexia
88 Grade 2 rash with pain, edema, ulceration
97 Diarrhea and limb edema
98 Diarrhea and dyspepsia
101 Emesis and nausea (grade 3)
104 Malnutrition, profuse diarrhea, limb edema
105 Rash and edema (grade 3)
114 ALT and AST increase
115 Rash/desquamation, edema, water retention
121 Mucositis (grade 3)
127 Cutaneous rash
128 Fatigue and erectile dysfunction
139 Diarrhea (grade 3)
143 Fatigue and nausea
146 Prolonged neutropenia
189 ALT and AST increase
189 Skin rash (grade 3)
201 Conjunctivitis (bleeding)
228 Myocardial infarction
246 Hepatotoxicity
257 Bilateral pulmonary infiltrates
273 Edema (head and neck), viral infection, cognitive disturbance, fatigue
275 Abdominal pain and total bilirubin increase
305 Asthenia (grade 2)
310 High transaminase level because of autoimmune hepatitis
319 High liver function tests
431 Depression (grade 3)
441 Vomiting and fatigue
446 Fatigue and edema (head and neck)
466 Pancreatitis
474 Pain in bones
509 Breathlessness and weight gain
515 Pneumonia, acute respiratory insufficiency, acute circulation insufficiency
550 Asthenia, mucositis, neutropenia, thrombocytopenia
628 Rash
647 Gastroenteritis and dehydration
656 Right arm pain (arthritis)
685 Thrombosis (grade 2)
719 Neutropenia
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Table A2.Main Toxicities (grade 3 and/or 4; reported in  2.5% of patients)
Toxicity Patients in Imatinib Arm (%)
Neutropenia 6.2
Weight loss or gain 3.3
Infections 3.1
ALT increase 2.8
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